# Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML

> **NCT06110208** · EARLY_PHASE1 · TERMINATED · sponsor: **920th Hospital of Joint Logistics Support Force of People's Liberation Army of China** · enrollment: 3 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** CLL1 and CD38 dual-target CAR-T injection

## Key facts

- **NCT ID:** NCT06110208
- **Lead sponsor:** 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-10
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Collaborator's decision
- **Last updated:** 2025-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06110208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06110208, "Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06110208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*